1/54
Looks like no tags are added yet.
8 hallmarks of cancer
self-sufficiency in growth signaling
insensitivity to growth inhibition
limitless replication potential
evasion of apoptosis
neo-angiogenesis
tissue invasion and metastasis
metabolic reprogramming
evasion of immune system
how far away from a blood vessel can cancer cells survive
human melanoma: 85um
rat prostate cancer: 110um
EF5 staining
clinical test to test for oxygen
if EF5 is oxygenated, will convert to EF5-S-Cys-ptotein covalent adducts which can be visualized in staining. if no staining that means no oxygen present
visualize hypoxic areas → farther away from blood vessels have less staining
how did they determine if tumor growth requires angiogenesis
followed tumor growth in two regions of eye
both had all nutrients necessary provided
large growth in iris, which is able to support angiogenesis
no growth in anterior chamber, which is NOT able to support angiogenesis
what happens when breast cancer cells are injected into angiogensis-deficient mice
no tumors
angiogenesis-deficient mice KO genes
het ld1
full KO ld3
tumor blood vessel growth happens via
upregulation of vascular endothelial growth factor (VEGF)
VEGF
vascular endothelial growth factor
upregulation allows for tumor blood vessel growth
angiogenesis positive feedback loop
tumors cause increased angiogenesis
new blood supply causes increased tumor growth
what cells contribute to angiogenesis
nude mouse transplanted with human HSCs, mouse tumor cells implanted, human endothelial markers found in new vasculature
human endothelial markers PECAM, CD34, VEGFR2 in blood vessels
angiogenesis recruits from endothelial cells in bone marrow, not tumor cells
mechanisms of blood vessel formation
sprouting angiogenesis
vasulogenesis
vascular mimicry
tumor cell → EC differentiation
sprouting angiogenesis
tip cell extrudes and connects to another tube, forming circle so nutrients can travel
vasulogenesis
endothelial precursor cells differentiate into endothelial cells
vascular mimicry
tumor cells line new blood vessels
tumor cell → EC differentiation
cancer stem-like cells differentiate into ECs
only way to differentiate is with genetic analysis
normal tissue vasculature
linear vessels
smooth layers of endothelium
supported by pericytes
tumor tissue vasculature
irregularly shaped vessels
many dead-ends
two few pericytes (less stable)
leaky
more thick and rigid matrix
what happens to pH of cells as O2 levels decrease (moving away from blood vessel)
decreasing pH, cells make more lactic acid
HIF1/2
upregulated in hypotoxic environments → induces transcription of genes for glycolysis, CA IX/XII (pH regulation), GLUT1,3 (glucose transporter), VEGF (angiogenesis)
PHD and FIH
O2 sensitive regulators of HIF-alpha via hydroxylation
PHDs hydroxylate Pro on HIF-alpha, causing VHL-mediated proteolysis → inactivation of HIF transcriptional activity
FIH hydroxylates Asn on HIF-alpha, causing blocked p300 (co-activator) recruitment → also inactivation of HIF transcriptional activity
HIF-alpha in high and low O2
high: active hydroxylases PHD and FIH → inactivate HIF transcriptional activity
low: inactive hydroxylases → co activators recruited → activation of transcriptional activity (50 fold upreg)
loss of VHL
in 90% of renal clear cell carcinoma (RCC) (most common form of kidney cancer)
van Hippel-Lindau syndrome
1:30,000
constitutively active hypoxia sugnaling
cancers from loss of VHL
RCC carcinoma (usually both kidneys)
hemangioblastoma (blood vessel tumors in brain, spinal cord, eye)
pheochromocytoma (adrenal gland tumor)
pancreatic neuroendocrine tumors
HIF2-alpha
key oncogene target of VHL in RCC
mutated VHL highly upregulates HIF2alpha → transcription factor PAX8 → more cyclin D1 and myc (uncontrolled proliferation and transformation)
major mechanisms regulating HIF1alpha/2alpha levels
O2 availability
control via protein synthesis
ROS mediated inhibition of PHDs
inhibition of PHDs by oncometabolites
O2 availability controls HIF-1/2 alpha degradation
1° mxn in hypoxia
decreased O2 → decreased OH-HIF-alpha → increased HIF-alpha
HIF1alpha/2alpha level control via protein synthesis
growth signaling dependent, oncogene dependent
increased signaling, increased HIF-1alpha translation
HIF1alpha/2alpha level control via ROS mediated inhibition of PHDs
2° mxn in hypoxia
decreased O2 → increased mitoROS —| PHDs (Cys-SH oxidation) → decreased OH-HIF-alpha → increased HIF-alpha
HIF1alpha/2alpha level control via inhibition of PHDs by oncometabolites
mutated Krebs cycle enzymes
oncometabolites —| PHDs → decreased OH-HIF-alpha → increased HIF-alpha
hypoxic tumor prognosis trend
likely poorer prognosis
tumor is able to live in unfavorable environments
hypoxic areas also are low pH which is an immunosuppressive environment
solutions to tumor hypoxia
spreading along existing blood vessels (glioma/glioblastoma)
invasion into surrounding tissues with normal O2 and nutrients (HIF1 dependent response)
rationale for anti-angiogenic therapy
majority of tumors require angiogenesis for growth
adult tissues have no need for new blood vessels
allows for avoidance of drug resistance
issue: have to take forever, turns cancer into chronic disease
inhibitors of angiogenesis clinical testing
avastin
endostatin
avastin
anti-VEGF antibody
proven efficacy for colon and renal cancer
side effects: cardiovascular
endostatin
natural angiogenesis inhibitor
failed in clinical trials
ASMase
acidic sphinogomyelinase
breaks down sphingomylein to ceramide causing apoptosis
ASMase KO mice have increased tumor volume
antitumor effects of radiation
direct: inhibits tumor cells → tumor shrinkage
indirect: inhibits endothelial cells → tumor shrinkage
anti-VEGF therapy clinical results
no tumor dormancy (initial predictions)
ineffective alone
works in combination with chemotherapy (matastatic lung, colon, renal, NOT breast (no survival benefit))
initial delay in tumor growth but not survival benefit (ovarian cancer, glioblastoma)
how can tumor angiogenesis be clinically beneficial
normal to extra vessel formation can allow for better drug delivery/response, immune access, less aggressive tumors
issues with blood vessel eradication
initial shrinkage but then regrowth of aggressive cancer, poor drug/immune access
cells on periphery that survive bc they’re closer to blood vessels and then are more aggressive
anti-VEGF therapy reduction of immunosuppression
VEGF-R is expressed on T killer cells. VEGF activates and causes exhaustion and loss of activity
inhibiting VEGF means it never binds
warburg effect
aerobic glycolysis in cancer
metabolism of glucose through lactic acid in the presence of O2
hallmark of cancer
caused by increased HIF-1
metabolic addiction of cancer 1: high glucose usage
warburg effect → decreased OxPhos & increased PI3K-AKT → increased glucose uptake
PET imaging of lymphoma with radioactive FDG
PET = positron-emission tomography
FDG = fluorodeoxyglucose → enters cells but gets trapped (not metabolized) → detected by positron emission
90% specificity and sensitivity for primary/metastatic cancers
PET-FDG limitations
high background in brain bc brain uses lots of glucose
benefit of PET-CT imaging in clinical response
CT will show abnormalities past metastatic tumors (as a scar)
PET shows when no longer active tumor
why do cancer cells have constitutively active glycolysis
competition for resources (GLUT1 high Vmax, GLUT3 low Km)
adaptation (rapid cycles of hypoxia and normoxia; increased carbonic anhydrases)
lactate as another energy source
immune escape (high acidity)
invasiveness (low pH kills neighbors)
metabolism of cancers
similar to fetal metabolism; embryonic and cancer cells need to proliferate lots
use warburg effect which produces fatty acids and nucleotides → needed for biosynthesis
PKM2
pyruvate kinase M2
overexpressed in tumors, fetal tissues and stem cells phosphate transfer from PEP to ADP to generate ATP
warburg effect molecular basis
HIF1 shuts down pyruvate to acetyl CoA transition and increased LDHA (lactate dehydrogenase) → more lactic acid and less TCA
mutated isocitrate dehydrogenase (IDH) in cancer
glioma, AML
majority of gliomas have mutated IDH1/2
cause alpha ketoglutarate → 2 ketoglutarate, an oncometabolite instead of succinate
IDHmut inhibitor has clinical approval
oncometamolites from mutations in krebs cycle enzymes
IDHmut → 2-ketoglutarate
SDHmut → highly upregulated succinate
FHmut → highly upregulated fumarate
three are all inhibitors of alphaKG dependent dioxygenases
metabolic addition of cancer 2: glutamine
nitrogen source and alternative energy source
nitrogen source for biosynthetic reactions
Gln → Glu → alphaKG for krebs
PET-Gln imaging
instead of PET-FDG (lots of background signal bc glucose, so hard to see tumor)
modify to use glutamine bc brain doesn’t use, so way less background
regulation of intracellular pH in hypoxic cells
CA IX needed for pH regulation → silencing decreases tumor size